Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Crevoisier

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
European Neurology|March 31, 1998
Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's diseaseJ Dingemanse, C H Kleinbloesem, C Crevoisier, et al.
Arzneimittel-Forschung|January 1, 1981
[Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)]C Crevoisier, M Eckert, P Heizmann, et al.
British Journal of Clinical Pharmacology|July 1, 1997
Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokineticsJ Dingemanse, C H Kleinbloesem, G Zürcher, et al.
Annals of Tropical Medicine and Parasitology|October 1, 1995
The chemotherapy of rodent malaria. LII. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomersW Peters, B L Robinson, M L Mittelholzer, et al.
British Journal of Cancer|September 1, 1993
Bioavailability and feasibility of subcutaneous 5-fluorouracilM M Borner, J Kneer, C Crevoisier, et al.
European Neurology|May 27, 1999
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's diseaseU E Gasser, K Jorga, C Crevoisier, et al.
Arzneimittel-Forschung|January 1, 1981
[Relationship between clinical effects and pharmacokinetics of midazolam on i.m. and i.v. application to volunteers/1st comm.: Clinical aspects (author's transl)]W H Ziegler, J D Thurneysen, C Crevoisier, et al.
Journal of Pharmaceutical Sciences|June 1, 1994
Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple dosesF Gimenez, R A Pennie, G Koren, et al.
European Journal of Pediatrics|June 1, 1993
Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo studyE Martin, S Fanconi, P Kälin, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1994
Pharmacokinetics of ceftriaxone in patients with typhoid feverG Acharya, C Crevoisier, T Butler, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Neurology|March 31, 1998
Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's diseaseJ Dingemanse, C H Kleinbloesem, C Crevoisier, et al.
Arzneimittel-Forschung|January 1, 1981
[Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)]C Crevoisier, M Eckert, P Heizmann, et al.
British Journal of Clinical Pharmacology|July 1, 1997
Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokineticsJ Dingemanse, C H Kleinbloesem, G Zürcher, et al.
Annals of Tropical Medicine and Parasitology|October 1, 1995
The chemotherapy of rodent malaria. LII. Response of Plasmodium yoelii ssp. NS to mefloquine and its enantiomersW Peters, B L Robinson, M L Mittelholzer, et al.
British Journal of Cancer|September 1, 1993
Bioavailability and feasibility of subcutaneous 5-fluorouracilM M Borner, J Kneer, C Crevoisier, et al.
European Neurology|May 27, 1999
COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa/benserazide. A novel principle in the treatment of Parkinson's diseaseU E Gasser, K Jorga, C Crevoisier, et al.
Arzneimittel-Forschung|January 1, 1981
[Relationship between clinical effects and pharmacokinetics of midazolam on i.m. and i.v. application to volunteers/1st comm.: Clinical aspects (author's transl)]W H Ziegler, J D Thurneysen, C Crevoisier, et al.
Journal of Pharmaceutical Sciences|June 1, 1994
Stereoselective pharmacokinetics of mefloquine in healthy Caucasians after multiple dosesF Gimenez, R A Pennie, G Koren, et al.
European Journal of Pediatrics|June 1, 1993
Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo studyE Martin, S Fanconi, P Kälin, et al.
Antimicrobial Agents and Chemotherapy|October 1, 1994
Pharmacokinetics of ceftriaxone in patients with typhoid feverG Acharya, C Crevoisier, T Butler, et al.
Pageof 4